Interventional trial using whole genome sequencing detects minimal residual disease in plasma for high-risk smoldering myeloma, suggesting improved monitoring methods.
Key Points
To evaluate the effectiveness of whole genome sequencing of cell-free DNA for assessing minimal residual disease in patients with high-risk smoldering multiple myeloma.
Used whole genome sequencing of baseline marrow and plasma samples
Developed an ultra-sensitive tumor-informed detection approach (MRDetect)
Compared plasma MRD results with bone marrow assessments for accuracy
CFDNA WGS detected MRD+ in 93% of cases where marrow was positive
Increased baseline tumor fraction linked to disease progression
Five out of seven patients with disease progression were plasma MRD+ at end of therapy